Engineers Refine Gene-Editing for Cystic Fibrosis

New precision tool could enable safer, more reliable therapies for genetic diseases

Published on Feb. 24, 2026

Got story updates? Submit your updates here. ›

Engineers at the University of Pennsylvania and Rice University have refined a technology for editing individual genetic "base pairs" to a new level of precision, opening the door to safer, more reliable therapies for a wide range of genetic diseases, and to potential treatments for some cystic fibrosis patients that may yield better outcomes than existing therapies.

Why it matters

Genetic diseases often require extremely specific therapies, which can vary from patient to patient, even for the same disease. The new gene-editing tool could enable more precise treatments for cystic fibrosis and other conditions caused by single-letter DNA changes, potentially leading to more effective and safer therapies.

The details

The researchers shortened and stiffened the "linker" that connects the two essential components of the base-pair editor - the part that locates a specific DNA sequence and the part that modifies it. This limited the enzyme's reach, ensuring it only edited the target letter and not neighboring ones. They also weakened the editor's tendency to act on nearby letters. In tests, the refined editor reduced unintended "bystander" edits by over 80% while retaining high activity at the target site.

  • The research was published on February 24, 2026.

The players

Xue "Sherry" Gao

Presidential Penn Compact Associate Professor in Chemical and Biomolecular Engineering (CBE) and in Bioengineering (BE) within Penn Engineering, and co-senior author of the study.

Tyler C. Daniel

A Penn Engineering doctoral candidate in CBE and co-first author of the study.

Gang Bao

Foyt Family Professor of Bioengineering at Rice University and a co-senior author of the study.

Got photos? Submit your photos here. ›

What they’re saying

“More than a thousand different genetic mutations can cause cystic fibrosis. The fact that different mutations require distinct corrective tools highlights the importance of precision medicine.”

— Xue "Sherry" Gao, Presidential Penn Compact Associate Professor (Mirage News)

“It's a bit like editing a document. We can already identify and replace a particular letter in a specific word. How do we change only that one letter without accidentally altering the letters next to it?”

— Xue "Sherry" Gao, Presidential Penn Compact Associate Professor (Mirage News)

“The more precise we can make these tools, the greater their potential to change how we treat genetic disease with a high level of efficacy and safety.”

— Gang Bao, Foyt Family Professor of Bioengineering (Mirage News)

What’s next

The research remains at an early, preclinical stage, but the refined gene-editing tool shows promise for treating cystic fibrosis and other genetic diseases caused by single-letter DNA changes.

The takeaway

This new precision gene-editing technology could enable safer and more effective treatments for cystic fibrosis and a wide range of other genetic diseases, moving the field of precision medicine forward and offering hope for patients with rare, hard-to-treat genetic conditions.